Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction

Gokkaya, Serkan; Özden, Cüneyt; Ozdal, Ozdem Levent; Koyuncu, Hakan; Güzel, Özer; Memiş, Ali

doi:10.1080/00365590801950279

Cited by 34 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19,21,22,26 Our results do not support this supposed improved response to iPDE5 after the use of simvastatin, although the studies that signal this endothelial modulation used atorvastatin. 16,18,19,22,23,26 It may be that the improved response to iPDE5 reported in these studies is related to the potency of the statin s À1 used. This is suggested by three randomized clinical trials using atorvastatin (from 40 to 80 mg daily), that showed a significant improvement in ED compared with the placebo 19,21,26 after less than 6 months using the medication.…”

Section: Values Expressed In Median (Percentile 25-75) C Values Exprcontrasting

confidence: 56%

“…27 Some authors showed that the treatment of dyslipidemia with The effect of simvastatin in penile erection ET Mastalir et al statins can determine the improvement of ED in selected patients. 16,18,19,[21][22][23]26 The explanations of how statins could improve ED are based mainly on the pleiotropic effects of this class of medication, that is, effects that go beyond simply lowering cholesterol levels. 7,8 Outstanding among these effects are the stabilization and posterior reduction of the atherosclerotic plaque, improved endothelial function and regulation of NO production, with consequent arteriolar vasodilation and diminished inflammatory activity, oxidative stress and thrombotic events.…”

Section: Values Expressed In Median (Percentile 25-75) C Values Exprmentioning

confidence: 99%

“…8,[13][14][15] By contrast, more recent studies have suggested the possibility that statins may improve ED in men with endothelial dysfunction. [16][17][18][19][20][21][22][23][24][25][26] Therefore, research evaluating the potential benefit of statin use in the treatment of men with ED determined by endothelial dysfunction is needed, especially regarding the pleiotropic effects of this class of medication.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction—STED TRIAL)

2011

View full text Add to dashboard Cite

The aim of the study is to evaluate the effect of simvastatin in erectile dysfunction (ED) secondary to endothelial dysfunction. This study is a double-blind, randomized, placebo-controlled, clinical trial in patients with ED and endothelial dysfunction. Patients were randomized to receive 20 mg simvastatin (n ¼ 21) or placebo (n ¼ 20) daily for 6 months and subsequently 10 mg of vardenafil on demand for 4 weeks. Serum cholesterol, hormone profile, ultrasensitive C-reactive protein, the International Index of Erectile Dysfunction (IIEF) and the ED Index of Treatment Satisfaction were evaluated. There was a significant reduction in serum cholesterol in the treatment group. The hormonal profile remained unaltered. There was no difference in the IIEF between the groups at follow-up, although, at the beginning, 26% of the patients of both groups presented with mild ED and 74% with moderate-to-severe ED; at the end of the 7th month, all patients from the simvastatin group progressed to mild ED, compared with only 83% in the placebo group. There was no statistically significant difference in penile erection after intake of simvastatin or placebo. This study does not support the use of simvastatin as erectogenic medication. Further studies are necessary to verify if simvastatin has any beneficial effect on ED.

show abstract

Section: Values Expressed In Median (Percentile 25-75) C Values Exprcontrasting

confidence: 56%

Section: Values Expressed In Median (Percentile 25-75) C Values Exprmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction—STED TRIAL)

2011

View full text Add to dashboard Cite

show abstract

“…127,128 There have been several reports of improvements in erectile function among men using statins with and without PDE5 inhibitors. [129][130][131][132] However, these findings are not consistent with those of Solomon et al, 133 who reported new-onset ED in 22% of 93 high-risk men after 6 months of statin use. Placebo-controlled studies of erectile function in men taking medications to control other cardiovascular risk factors are lacking.…”

Section: Mayo Clinic Proceedingsmentioning

confidence: 59%

The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease

Nehra

Jackson

Miner

et al. 2012

Mayo Clinic Proceedings

417

341

View full text Add to dashboard Cite

The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative tradition dedicated to optimizing sexual function and preserving cardiovascular health. The third Princeton Consensus met November 8 to 10, 2010, and had 2 primary objectives. The first objective focused on the evaluation and management of cardiovascular risk in men with erectile dysfunction (ED) and no known cardiovascular disease (CVD), with particular emphasis on identification of men with ED who may require additional cardiologic work-up. The second objective focused on reevaluation and modification of previous recommendations for evaluation of cardiac risk associated with sexual activity in men with known CVD. The Panel's recommendations build on those developed during the first and second Princeton Consensus Conferences, first emphasizing the use of exercise ability and stress testing to ensure that each man's cardiovascular health is consistent with the physical demands of sexual activity before prescribing treatment for ED, and second highlighting the link between ED and CVD, which may be asymptomatic and may benefit from cardiovascular risk reduction. T he Princeton Consensus Conference is a multispecialty collaborative tradition dedicated to optimizing sexual function and preserving cardiovascular health. The first conference convened in June 1999 to develop recommendations for clinical management of sexual dysfunction in men and women with known cardiovascular disease (CVD). This conference also provided a multidisciplinary forum for evaluation of the potential cardiovascular risk posed by sexual activity in atrisk patients. The first Princeton Consensus Conference recommendations 1 included stratification of patients by level of cardiac risk associated with sexual activity based on existing CVD. Those at low risk could initiate or resume sexual activity and be treated for sexual dysfunction. For those at high risk, sexual activity was deferred until the cardiac condition was stabilized. The second Princeton Consensus Conference convened in June 2004 and expanded the recommendations of the first conference to emphasize risk factor evaluation and lifestyle management for all men with erectile dysfunction (ED). 2 The second conference recommendations also incorporated new information on the appropriate use of phosphodiesterase type 5 (PDE5) inhibitors in men with ED and concomitant CVD.The third Princeton Consensus Conference took place November 8 to 10, 2010, in Miami Beach, Florida. The group revisited and updated their 2005 recommendations regarding the cardiovascular risk associated with sexual activity in men with known CVD. 2 In addition, the third conference focused on the predictive value of vasculogenic ED in assigning cardiovascular risk in men of all ages, with the primary objective being development of an approach to cardiovascular risk assessment in younger men with ED and no known CVD. The role of testosterone in erectile function and cardiovascular health and the utility of testosterone replacement...

show abstract

“…Importantly, the benefits of statin therapy are evident in subjects with mild to moderate CKD but not in those receiving dialysis (as in the 4D trial), strongly supporting early initiation of statin treatment in CKD. 46 There are a number of reports of improved erectile function in men receiving statins with and without phosphodiesterase-5 (PDE5) inhibitors, 48,49 but a recent report showed a high rate of new-onset ED (22 per cent of 93 men after six months of statin use) in subjects with high CV risk, 50 suggesting that late initiation of statin in older patients with comorbidities such as diabetes and multiple CV risk factors may be less effective.…”

Section: Lipid-lowering Therapymentioning

confidence: 99%

New approaches to assessing cardiovascular risk

Masi

Charakida

Deanfield³

2013

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction

Cited by 34 publications

References 19 publications

The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction—STED TRIAL)

The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction—STED TRIAL)

The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease

New approaches to assessing cardiovascular risk

Contact Info

Product

Resources

About